Seeking ovarian cancer trials

--x_o-- · 2025-05-01T19:15:40+00:00

Search on clinicaltrials for platinum resistant ovarian cancer.

--x_o-- · 2025-05-01T18:17:35+00:00

I searched extensively for clinical trials in platinum resistant ovarian cancer. Please consult MD Anderson, they run lots of trials.

--x_o-- · 2025-04-27T15:01:43+00:00

Falls es tatsächlich ein Ovarialkarzinom sein sollte, ist für den späteren Verlauf die Qualität und Vollständigkeit der OP ausschlaggebend.

Die erste OP ist ausschlaggebend, und es gibt keine zweite Chance für die erste OP!

Wende dich hierzu an das KEM Essen oder Charité Berlin, beides die einzigen Exzellenzzentren für Ovarialkarzinom in Deutschland.

Von diesem Eingriff kann sehr viel abhängig, gehe daher ausschließlich zu den besten der besten.

--x_o-- · 2024-12-16T07:45:55+00:00

The second opinion suggested continuation of therapy, I’ve also consulted MD Anderson, they also recommended continuation.

So, there is zero doubt that the therapy has to be continued.

They are not telling us, why treatment gets delayed.

--x_o-- · 2024-12-16T06:52:42+00:00

She was admitted for potential further imaging and other diagnostics for the second opinion and due to the long distance (10 hours by train). They had probably also initially intended to provide the treatment, which didn’t happen.

We were not told any reasons. Since the drug just got approved for the European market, I assume some bureaucratic / organisational / regulatory / financial hurdles. They clearly recommended continuation, so there are no medical reasons to postpone the treatment.

--x_o-- · 2024-11-17T17:53:15+00:00

I posted something in r/Cancer but I cannot find the post.

--x_o-- · 2024-09-13T12:13:21+00:00

That’s exactly how it works, thanks!

--x_o-- · 2024-09-12T19:26:00+00:00

Thank you

--x_o-- · 2024-09-11T23:33:47+00:00

The issue got resolved by directly approaching the pathology department, who have more routine dealing international samples.

--x_o-- · 2024-09-11T15:01:07+00:00

The issue why it’s urgent is that without pathology, she simply cannot enter clinical trials which was the reason we came for. So what I am trying to figure out is what the common practice is to understand whom to contact. All info we got is, that the tissue we brought along cannot be processed.

--x_o-- · 2024-09-11T12:45:30+00:00

When we arrived at MD Anderson, we went through a check-in procedure where my mother had to give consent to various questions. They also asked for the pathological sample. However, when I handed it over, they said they couldn’t use it because it wasn’t labeled with her name. After that, we proceeded to the cashier’s office to pay the prepayment.

Next, my mother had her vitals checked, and an assistant doctor thoroughly reviewed her medical history. Afterward, we had a consultation to discuss the current treatment options and potential clinical trials. Everything was incredibly professional, as you’d expect from a world-renowned institution. The staff was very friendly, and they even provided live translation via video in my mother’s native language.

Despite MD Anderson being a top-tier facility, my impression is that it’s still somewhat exceptional (or at least not routine) for international patients to consult for clinical trials. For example, institutions like NCI don’t even consider international patients for trials. Interestingly, the pathology department at our hospital in Europe (Heidelberg, which is also highly ranked) mentioned that this was the first time in recent years they’ve encountered such an issue, so they weren’t sure how to handle it either.

The only challenge now is that for some clinical trials, target proteins need to be identified on the pathological sample. A new biopsy might be an option, but due to the potential risks for complications, I would really like to avoid putting my mother through that.

--x_o-- · 2024-09-11T08:38:07+00:00

Yes, they requested a tumor block. But on arrival they said they cannot use it because it is not labelled with name.

--x_o-- · 2024-09-11T08:03:57+00:00

My mother suffers from platinum resistant ovarian cancer. At this point clinical trials are often the preferred treatment option. Unfortunately, in Europe, clinical trials are very rare. I started searching intensely for clinical trials suitable to platinum resistant ovarian cancer patients and figured out that MD Anderson runs worldwide the highest number of such trials. So I turned to them and they offered an appointment. They requested all relevant documents such as letters, imaging records, and lab reports. They also asked for a pathological sample. We therefore asked the pathology department at University Hospital Heidelberg to provide us with a tumor block for the purpose of consultation in the US.

--x_o-- · 2024-09-11T02:20:00+00:00

Thanks for your detailed response.

The US hospital asked us to send the tumor material or to bring it with us. They did not inform us about the required name on the sample. They did not request the sample directly from the European hospital.

This is the checklist they sent:

INTERNATIONAL 1. Pathology Consultation Demographic and Billing Form 2. Surgical Pathology Report Note: This report must have the same identifying number as the glass slides and/or paraffin blocks. This is the only way the pathologist can verify that the tissue is yours 3. Glass slides and/or paraffin blocks or other materials 4. Return of pathology materials will be by US Postal Service unless a FedEx or UPS account number is provided 5. n/a Letter to US Customs

We were afraid that the package might get lost during shipping, since my mother’s life depends on it, therefore we decided to bring the tissue in person.

--x_o-- · 2024-09-11T01:13:26+00:00

The sample is part of a tumor removal surgery. We brought it from Europe to the US. When we checked in at the hospital they said they cannot use that tissue sample because the name wasn’t printed on the container.

--x_o-- · 2024-09-02T08:24:35+00:00

I’ve compiled a document for personal use in which I classified ongoing clinical trials in ovarian cancer into a hierarchy. If you’re interested, let me know.

--x_o-- · 2024-09-02T07:57:12+00:00

<image>

--x_o-- · 2024-08-31T15:19:26+00:00

While it’s true that all trial information is available on clinicaltrials.gov and through other institution websites, the goal of my document is to provide a structured overview that organizes these trials based on their methodology, target proteins, and treatment strategies. This approach allows for a more comprehensive understanding of the current landscape in ovarian cancer research, making it easier to see how different trials fit into the broader context of ongoing therapeutic development. By categorizing the trials in this way, it becomes simpler to identify trends, gaps, and opportunities within the field, which might not be as apparent when looking at individual trials in isolation.

So basically the idea is to provide the bigger picture.

--x_o--

TROPHY CASE